Braga M, Zerbi A, Malesci A, Dal Cin S, Valentini A, Tacconi M, Erenbourg L, Paganelli M, Di Carlo V
Department of Surgery, Scientific Institute San Raffaele, Milan, Italy.
Pancreas. 1993 Jul;8(4):494-8. doi: 10.1097/00006676-199307000-00014.
The complete control of steatorrhea in post-surgical exocrine pancreatic insufficiency is difficult. The aim of this study was to evaluate the effect of the association of ranitidine with pancrelipase om fecal fat excretion in patients who had undergone a pancreatoduodenectomy with suppression of the exocrine pancreatic secretion by Neoprene injection. Ten patients were studied 1 year after surgery. Steatorrhea was measured as an integrated test of 3-day stools, while patients were kept on a diet of 100 g lipid/day, with their usual enzyme supplementation therapy (16,050 USP units of lipase/meal). A basal 24-h gastroenteric pH profile was also obtained. In the following month, patients had ranitidine (150 mg twice a day) in addition to pancrelipase. Then steatorrhea and gastroenteric pH were reassessed. Mean fecal fat was 26.9 (SD 13.7) g/day without ranitidine and 30.5 (SD 13.9) g/day during combined treatment. Body weight and nutritional parameters did not show any significant variation after ranitidine administration. Even in the absence of ranitidine, postprandial gastroenteric pH values were always > 4; the H2-receptor antagonist only reduced fasting gastric acidity. In conclusion, the gastroenteric pH and fecal fat determinations showed that ranitidine is not useful in patients with total postsurgical exocrine pancreatic insufficiency.
外科手术后外分泌性胰腺功能不全患者的脂肪泻完全控制起来较为困难。本研究的目的是评估雷尼替丁与胰酶片联合使用对经氯丁橡胶注射抑制外分泌性胰腺分泌后接受胰十二指肠切除术患者粪便脂肪排泄的影响。对10例患者术后1年进行了研究。脂肪泻通过连续3天粪便的综合检测来衡量,同时患者维持每天100 g脂质的饮食,并接受常规的酶补充治疗(每餐16,050 USP单位脂肪酶)。还获取了基础24小时胃肠pH值曲线。在接下来的一个月里,患者除了服用胰酶片外,还加用了雷尼替丁(150 mg,每日2次)。然后重新评估脂肪泻和胃肠pH值。未服用雷尼替丁时平均粪便脂肪为26.9(标准差13.7)g/天,联合治疗期间为30.5(标准差13.9)g/天。服用雷尼替丁后体重和营养参数未显示任何显著变化。即使在未服用雷尼替丁的情况下,餐后胃肠pH值也始终>4;H2受体拮抗剂仅降低了空腹胃酸度。总之,胃肠pH值和粪便脂肪测定结果表明,雷尼替丁对术后完全性外分泌性胰腺功能不全患者无效。